Shenzhen Kangzhe, a subsidiary of China Medical System (00867), Selected for “2020 Shenzhen Top 500 Enterprises”

Company News

October 20, 2020, under the guidance of China Enterprise Confederation and China Enterprise Directors Association, and hosted by Shenzhen Enterprise Confederation and Shenzhen Enterprise Directors Association, the “Glorious 40 Years, The Demonstration Zone for Homeland – The Release of 2020 Shenzhen Top 500 Enterprises List and Industry Leadership Forum” was grandly held in Shenzhen Convention and Exhibition Center. The “2020 Shenzhen Top 500 Enterprises” list was published at the forum and Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS”) was once again selected, ranking 117 and up 8 places compared with year 2019. The list, which is an authoritative ranking for Shenzhen enterprises, is based on various production and operation indicators of the selected enterprises and reflects the current status, achievements made and future development trends of enterprises in Shenzhen in year 2020 comprehensively, systematically and truthfully.

Capitalizing on the high-quality product portfolio, the comprehensive, professional and compliant academic promotion system, and the efficient management, Shenzhen Kangzhe achieved steady growth for the past years. Being selected in the “Shenzhen Top 500 Enterprises” list again demonstrates the recognition and affirmation from authoritative institutions for the company’s operation management and social value. In the future, Shenzhen Kangzhe will work together with other members of the group to accelerate the commercialization of innovative drugs that are more effective, safer and more cost-effective in China market, so as to benefit Chinese patients and their families and add impetus to the long-term development of Shenzhen and the progress of China pharmaceutical industry.